NEWS
Healthgevity
Oct 02, 2026

Healthgevity Introduces hydraCELL+™, Featuring Formulation IP Developed by the Seeds Foundation for Cellular Research

BREAKING NEWS

INTERLAKEN, N.J., [October 2, 2026] — Healthgevity, a practitioner-focused precision longevity nutrition company, announced the launch of hydraCELL+™, a cellular hydration and muscle-support formula built on proprietary formulation IP developed through the Seeds Foundation for Cellular Research and licensed to Healthgevity.

The formula reflects the cellular medicine approach advanced by William Seeds, MD, and the Seeds Scientific Research & Performance Institute, bringing that foundation into a practical nutritional option for practitioners working in healthspan, weight management and performance care.

Muscle plays a central role in healthy aging, supporting mobility, metabolic health and physical resilience. Maintaining muscle strength and function is an important consideration during aging, caloric restriction and demanding training. hydraCELL+™ was developed to support muscle physiology through complementary approaches to cellular hydration, nutrient signaling and energy availability.*

Each serving combines 8 g of Pürest Creatine™ (creatine monohydrate), 10 g of trehalose, 5 g of L-alanine, 4 g of glycine, 3 g of L-glutamine and 3 g of L-leucine. The formula is organized around three complementary actions:

  • Volumize: Creatine supports intracellular hydration and healthy muscle cell volume.*
  • Signal: Leucine supports nutrient signaling involved in muscle protein synthesis.*
  • Perform: Creatine supports phosphocreatine availability and ATP regeneration for exercise performance.*

“Maintaining muscle is a priority across weight management, healthy aging and performance care,” said Michael Antonelli, Founder and CEO of Healthgevity. “hydraCELL+ brings the cellular medicine approach advanced by Dr. Seeds into a practical, research-informed formula that combines creatine and targeted amino acids to support cellular hydration, muscle signaling and performance.”

hydraCELL+™ is designed to complement adequate dietary protein, resistance exercise and individualized practitioner-directed care. Its ingredient foundation includes creatine monohydrate, an extensively studied nutritional ingredient for muscle strength and exercise performance. Ingredient research informs the formulation; it does not establish clinical outcomes for the finished product.

hydraCELL+™ is available now through Healthgevity practitioner wholesale accounts, with direct-to-patient ordering and fulfillment available through the Healthgevity HCP affiliate program.

For product details and directions, visit healthgev.com/products/hydracell.

Healthgevity is a Trusted Partner of SSRP, reflecting a shared commitment to supporting practitioners with science-informed tools, education and resources aligned with the evolving field of cellular medicine. Through the Trusted Partner Network, SSRP works with organizations that demonstrate a commitment to quality, scientific integrity and meaningful support of the SSRP provider community.

For more information and to view the Healthgevity Partner Page, visit:
SSRP Healthgevity Partner Page

About Healthgevity 

Healthgevity® develops practitioner-exclusive formulations built on Precision Signaling Nutrition™, combining bioactive peptides, biofunctional proteins and clinically informed nutraceuticals. Working alongside physicians, researchers and biotechnology innovators, Healthgevity develops nutritional tools for healthy aging, metabolic health, gut health and performance.


*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

RELATED RESOURCES

Continue exploring related topics.

VIEW ALL
SSRP Institute Nov 12, 2026
FDA Requires New Safety Warnings for GLP-1 Receptor Agonists Due to Potential Vision Risk
BREAKING NEWS [NOVEMBER 12, 2026] – On November 9, the U.S. Food and Drug Administration (FDA) announced new safety labeling requirements for glucagon-like peptide-1 receptor agonists (GLP-1 RAs), citing a potential increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a rare but serious condition that can cause sudden, painless vision loss, sometimes permanently. The […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Nov 9, 2026
Ep. 113 - Dr. Seeds' Office Hours
Preview only
Dr. Seeds’ Office Hours – Episode 113

1. Dr. Seeds explores the clinical priorities in a 50-year-old female kidney transplant recipient with lupus, chronic steroid use, IBS, fatigue, and reported low morning glucose, focusing on metabolic function, gut health, and preserving immune tolerance. [0:47

Preview Only — Become a member for full access
Promoitalia Nov 5, 2026
SSRP Institute Welcomes Promoitalia as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [November 5, 2026] — The SSRP Institute announces that Promoitalia has joined its Trusted Partner Network following nomination and completion of the SSRP’s internal review process. Promoitalia is an Italian aesthetic medicine company that develops professional technologies, methodologies, and consumable products for regenerative aesthetics and skin health. Its work combines professional […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Nov 2, 2026
Ep. 112 - Peptide Therapy Gets a Smarter Upgrade
Preview only
Dissecting Protocols – Episode 112

Peptide Therapy Gets a Smarter Upgrade

Dr. Seeds addresses the often-overlooked challenges of peptide purity, patient adherence, and administration. He also shares the journey behind the Redox Smart Pen, highlighting years of collaboration with scientists, physicians, and formulators to help raise the standard for peptide therapy and advance the future of cellular medicine.

Preview Only — Become a member for full access
SSRP Institute Oct 29, 2026
Dr. Seeds and Medivive Announce the Redox Smart Pen: A Novel Technology for Precise Peptide Administration
BREAKING NEWS WILLOUGHBY, Ohio [October 29, 2026] — Dr. Seeds and Medivive announce the launch of the Redox Smart Pen, an innovative pre-filled autoinjector peptide delivery system designed to improve precision and consistency in physician-directed peptide protocols. Importantly, the Redox Smart Pen was developed through a proprietary methodology focused on uniform potency, accuracy of administration, […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Oct 26, 2026
Ep. 111 - Can BPC-157 & HBOT Prevent Amputation?
Preview only
Dissecting Protocols – Episode 111

Can BPC-157 & HBOT Prevent Amputation?

Dr. Seeds explores the potential and limitations of these investigational approaches, emphasizing the importance of blood flow, patient phenotyping, and cellular function in limb salvage. (Question Link)

Preview Only — Become a member for full access
PharmaNutra Oct 22, 2026
SSRP Institute Welcomes PharmaNutra as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [October 22, 2026] — The SSRP Institute announces that PharmaNutra has joined its Trusted Partner Network following nomination and completion of the SSRP’s internal review process. Founded in Italy in 2003, PharmaNutra is a pharmaceutical and nutraceutical company focused on the research, development, and production of nutritional supplements and medical devices. […]
READ NEWS
VIDEO
Cellular Medicine Mondays
Oct 19, 2026
Ep. 110 - The Macrophage Mystery: Decoding Aging
Preview only
Rabbit Holes – Episode 110

The Macrophage Mystery: Decoding Aging

In Part 3 of our Anti-Aging Mini Mastermind, Dr. Seeds explores how aging alters PGE2/EP2 signaling, influencing macrophage metabolism, immune function, and inflammation, and examines potential therapeutic implications.
Articles referenced: (2026 Article) (2021 Article)

Preview Only — Become a member for full access
VIDEO
Cellular Medicine Mondays
Oct 12, 2026
Ep. 109 - Anti-Aging Mini Mastermind Part 2
Preview only
Journal Club – Episode 109

Anti-Aging Mini Mastermind Part 2

In Part 2 of our Anti-Aging Mini Mastermind series, Dr. Seeds explores how PGE2 signaling and cellular metabolism influence inflammation, cognitive function, and aging, connecting foundational research to emerging discoveries in immunometabolism.  (2026 Article) (2021 Article)

Preview Only — Become a member for full access
ARTICLE
William Seeds, MD
Oct 8, 2026
EP2, Tissue-Resident Macrophages, and a New Mechanism of Organ Aging
William Seeds, MD Oct 8, 2026
EP2, Tissue-Resident Macrophages, and a New Mechanism of Organ Aging
Revisiting a Journal Club Article, “Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging.” Science. 2026  Why This Paper Matters Most of the senescence conversation over the past decade has centered on a familiar cast: senescent fibroblasts, endothelial cells, adipocytes, and the drugs designed to clear them. This paper, which I discuss in […]
READ ARTICLE

Subscribe to the SSRP Community Digest

Get the latest research and developments in the field of Cellular Medicine straight to your inbox every month.

This field is for validation purposes and should be left unchanged.